Previous studies have reported that plasma ctDNA levels are correlated with tumor and metastatic burdens and that the loss of detectable ctDNA early in EGFR-TKI treatment is associated with favorable clinical outcomes [22, 23]. Here, EGFR is linked to neoplasm.